SCHEMBL2398945

SCHEMBL2398945

O=S(=O)(c1ccc(Cl)cc1)n1nccc1/C=C/c1cccs1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ LMNA P02545 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ NPSR1 Q6W5P4 4/20 0.42
▸ MAPT P10636 3/20 0.42
▸ MAPK1 P28482 1/20 0.41
▸ CYP2C19 P33261 2/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ MCOLN3 Q8TDD5 1/20 0.39
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ PKM P14618 2/20 0.37
▸ HPGD P15428 1/20 0.36
▸ TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2398947 1.00 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2LMNAL3MBTL1NPSR1
SCHEMBL1224871 0.79 PTGS1 (0.40) ALDH1A1SMN1; SMN2CYP1A2POLBTDP1
SCHEMBL1224872 0.79 PTGS1 (0.40) ALDH1A1SMN1; SMN2CYP1A2POLBTDP1
SCHEMBL2399771 0.72 F2 (0.48) ALDH1A1SMN1; SMN2LMNAMAPTCYP2C19
SCHEMBL2399767 0.72 F2 (0.48) ALDH1A1SMN1; SMN2LMNAMAPTCYP2C19
SCHEMBL1224357 0.72 MAPT (0.40) ALDH1A1LMNAL3MBTL1NPSR1MAPT
SCHEMBL1224360 0.72 MAPT (0.40) ALDH1A1LMNAL3MBTL1NPSR1MAPT
SCHEMBL1225516 0.71 SMN1; SMN2 (0.45) ALDH1A1SMN1; SMN2LMNANPSR1MAPT
SCHEMBL1225513 0.71 SMN1; SMN2 (0.45) ALDH1A1SMN1; SMN2LMNANPSR1MAPT
SCHEMBL9373561 0.66 RAB9A (0.56) ALDH1A1SMN1; SMN2LMNAL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110230407-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN DEMYELINATING DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2011-09-22 — — US claimed
US-20110230407-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN DEMYELINATING DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2011-09-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230407-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN DEMYELINATING DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA HGF, HGFAC, HDGF ALDH1A1 3300/4885SMN1; SMN2 112/4885LMNA 2759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback